<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01372085</url>
  </required_header>
  <id_info>
    <org_study_id>14318</org_study_id>
    <secondary_id>I3G-FW-JGCE</secondary_id>
    <nct_id>NCT01372085</nct_id>
  </id_info>
  <brief_title>Single Dose Study in Healthy Volunteers to Investigate the Safety and Absorption of LY2584702</brief_title>
  <official_title>A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, placebo-controlled, two-part study in healthy subjects.

      Part A will be a single dose, single period, placebo-controlled pilot study to explore the
      safety, tolerability, absorption and pharmacodynamic (effect of drug on a biological
      marker-pS6 levels in skin biopsies) of a single dose of 25 mg LY2584702 Reference formulation
      (RF). Part B is a single dose, placebo-controlled, 4-period crossover study to primarily
      evaluate the absorption of the Test Formulation (TF) in comparison with the (RF) of
      LY2584702.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Predose and up to 48 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, area under the concentration-time curve (AUC)</measure>
    <time_frame>Predose and up to 48 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the concentration of lipids</measure>
    <time_frame>Baseline and up to 24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Part A: 25 mg RF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 25 mg dose of LY2548702 Reference Formulation (RF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 10 mg dose of LY2548702 Test Formulation (TF) during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2584702 Reference Formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: 25 mg RF</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2584702 Test Formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Sequence 1</arm_group_label>
    <arm_group_label>Part B: Sequence 2</arm_group_label>
    <arm_group_label>Part B: Sequence 3</arm_group_label>
    <arm_group_label>Part B: Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male subjects:

        Agree to use a reliable method of birth control during the study and for at least 1 month
        following the last dose of study drug

        Female subjects:

        Women not of childbearing potential due to surgical sterilization (hysterectomy or
        bilateral oophorectomy or tubal ligation) or menopause. Women with an intact uterus are
        deemed postmenopausal if they are greater than or equal to 45 years old, who have not taken
        hormones or oral contraceptives within the last year, and had cessation of menses for at
        least 1 year, or who have had 6 to 12 months of amenorrhea with follicle-stimulating
        hormone (FSH) levels consistent with postmenopausal state.

          -  have a screening body mass index of 18.5 to 32.0 kg/m^2, inclusive

          -  have clinical laboratory test results within the normal range for the population or
             investigator site, or with abnormalities deemed clinically insignificant by the
             investigator. In particular, subjects should have normal or near normal screening
             liver tests at the discretion of the investigator

          -  have normal blood pressure and pulse rate (supine) at screening, or with minor
             deviations judged to be acceptable by the investigator

          -  have venous access sufficient to allow blood sampling as per the protocol

          -  are reliable and willing to make themselves available for the duration of the study
             and are willing to follow study procedures

          -  have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site

        Exclusion Criteria:

          -  are currently enrolled in, have completed or discontinued within the last 30 days
             from, a clinical trial involving an investigational product other than the
             investigational product used in this study; or are concurrently enrolled in any other
             type of medical research judged not to be scientifically or medically compatible with
             this study. Subjects that participate in Part A of this study may participate in Part
             B of the study if the first dosing in Part B is &gt;30 days after the dose of LY2584702
             or placebo in Part A.

          -  have known allergies to LY2584702, or related compounds

          -  have an abnormality in the 12-lead ECG (including but not limited to Bazett's
             corrected QT [QTcB] interval &gt;450 msec for men and &gt;470 msec for women)

          -  have a history within the last 2 years or presence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
             capable of significantly altering the absorption, metabolism, or elimination of drugs;
             of constituting a risk when taking the study medication; or of interfering with the
             interpretation of data

          -  have a history of drug or alcohol abuse, or regularly use known drugs of abuse

          -  show evidence of human immunodeficiency virus infection and/or positive human
             immunodeficiency virus (HIV) antibodies

          -  show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  intend to use over-the-counter or prescription medication within 14 days prior to
             dosing or during the study

          -  use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice,
             Seville oranges, or Starfruit within 7 days prior to study dosing or intended use
             during the study

          -  have donated blood of more than 450 mL within the last 3 months

          -  have an average weekly alcohol intake that exceeds 21 units per week (males) and 14
             units per week (females), or are unwilling to stop alcohol consumption from prior to
             dosing until the completion of each study period (1 unit = 12 oz or 360 mL of beer; 5
             oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

        Applicable for Part A only:

        â€¢ have known allergies to lignocaine, adrenaline, tetracycline, or related compounds, which
        will be used in the skin biopsy procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <last_update_submitted>October 7, 2011</last_update_submitted>
  <last_update_submitted_qc>October 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>September 27, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

